nytimes.com — The pharmaceutical company, Pfizer, said Wednesday that it was acquiring the rights to a promising experimental drug for Alzheimer’s disease from Medivation for as much as $725 million. Pfizer, which is seeking to bolster its pipeline of experimental drugs, will pay an initial $225 million for rights to the medicine, Dimebon, which is also being developed for Huntington’s disease, the companies said on Wednesday.
Add a live kick counter to your blog >>
You can even customize the image by choosing your own colors, and then clicking the button below to update the preview and the html code:
Simply copy and paste this HTML into your blog post.